DRUGS firm AstraZeneca has rejected an improved £69bn final takeover offer from US rival Pfizer.
Pfizer had made a new offer of £55 per share.
However, AstraZeneca says the new proposal undervalues the company and its attractive prospects.
Pfizer's pursuit has gained close scrutiny over fears it would hamper AstraZeneca's drug research and cut jobs.
The US company planned to create the world's largest drug company, with its headquarters in New York, but based in the UK for tax purposes.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article